Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018 ...Middle East

Developed in-house by internal R&D Team at Antengene, ATG-018 is an orally-available, small molecule ATR inhibitor that targets DNA Damage Response (DDR) pathways. The Phase I study will evaluate the safety, pharmacology and preliminary efficacy of ATG-018 in patients with advanced solid...

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018 )

Also on site :

• Rough start dooms SB Foresters
• NFC‑enabled music key cards
• Top Western firms switching to Chinese AI – WSJ